William Jarosz

AIG Brunswick Millennium Fund seeks investment opportunities in companies located in Russia, the Baltic States and other nations of the former Soviet Union. The fund targets companies operating in large infrastructure projects include power, transportation, natural resource development and related industries. It provides financing for buyout capital requirements with a minimum investment size of $7 million.

PineBridge Capital Partners LLC is a private equity firm located in New York City. The firm is a subsidiary of PineBridge Private Equity Group Partners and their ultimate parent is Hong Kong-based Pacific Century Group.

iCo Therapeutics, Inc. is a canadian biotechnology company. It engages in the business of identification, development and commercialization of drug candidates to treat ocular and infectious diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.

Cartesian Capital Group LLC (Cartesian Capital) is a private equity firm founded in 2006 by Peter Yu, Thomas Armstrong and Paul Pizzani. The firm is headquartered in New York.

Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.